ZEB2 and cancer: In contrast to SBF2-AS1, the remaining four antisense genes (MSC-AS1, KTN1-AS1, TM4SF19-AS1, and ZEB2-AS1) promote EMT, implicating their potential roles in promoting cancer progression.